Cantargia AB

CANTA

SE0006371126

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 10/06/2024 pm IST			5-day change	1st Jan Change
4.594 ^SEK	-3.20%		-8.12%	+22.90%

01/06	Cantargia Asco Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy	CI
23/05	Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy	CI

Cantargia AB Announces Claus Asbjørn Andersson Declined Re-Election

April 27, 2021 at 04:15 pm IST

Cantargia AB (publ) announced that Claus Asbjørn Andersson has declined re-election, at the annual general meeting, to be held on 26 May 2021.

Latest news about Cantargia AB

Cantargia Asco Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy	02/06	CI
Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy	24/05	CI
Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024	21/05
Cantargia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	17/04	CI
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	10/04	CI
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	09/04	CI
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	02/04	CI
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	27/03	CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	14/03	CI
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	06/03	CI
Transcript : Cantargia AB, 2023 Earnings Call, Feb 22, 2024	22/02
Cantargia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02	CI
Cantargia Secures US Approval to Start Patient Recruitment for Pancreatic Cancer Therapy	20/02	MT
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab	20/02	CI
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy	12/02	CI
Cantargia Reports Phase I Clinical Progress in the CAN10 Project	09/01	CI
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10	24/11	CI
Cantargia Maintains Patent for Cancer Treatment Amid Withdrawal of Third-party Appeal	20/11	MT
Transcript : Cantargia AB, Q3 2023 Earnings Call, Nov 10, 2023	10/11
Cantargia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Cantargia Seeks SEK59 Million from Share Sale	31/23/31	MT
Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer	28/23/28	CI
Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR	20/23/20	CI
Cantargia's Investigational Blood Cancer Drug Wins $1.1 Million External US Grant	18/23/18	MT

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.594 SEK

Average target price

12.67 SEK

Spread / Average Target

+175.72%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CANTARGIA AB	+22.90%	82.71M
VERTEX PHARMACEUTICALS INCORPORATED	+18.77%	125B
REGENERON PHARMACEUTICALS, INC.	+14.05%	108B
BIONTECH SE	-7.16%	24.21B
ARGENX SE	+2.07%	22.78B
GENMAB A/S	-10.79%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.47%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.23%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.13%	11.66B

Bio Therapeutic Drugs

Cantargia AB

Equities

CANTA

SE0006371126

Biotechnology & Medical Research

Cantargia AB Announces Claus Asbjørn Andersson Declined Re-Election

Latest news about Cantargia AB

Chart Cantargia AB

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs